Animal model research offers a new potential treatment for multiple sclerosis.
Compugen has reported new and promising results from studies on animal models of multiple sclerosis (MS) that support its lead drug candidate, CGEN-15001, as a potential treatment for a variety of autoimmune diseases, including MS.
Specifically, CGEN-15001 was shown to restore immune tolerance and balance in a durable and sustained manner in treated animals, a major unmet research goal for these diseases.
“Autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, type 1 diabetes and psoriasis, are conditions in which the immune system attacks the body’s healthy tissues due to loss of self-tolerance. Restoring this tolerance without impacting the immune system’s ability to fight other diseases is the Holy Grail of immunology,” Anat Cohen-Dayag, CEO and president of Compugen, said in a press release. “Currently, most drugs indicated for autoimmune diseases are general immuno-suppressants, which may lead to serious side effects including infections and an elevated risk of cancer.”
Read full article: Early MS Study in Mice Reports New Protein Restores Immune Balance
|Read Full Article: Early MS Study in Mice Reports New Protein Restores Immune Balance|